Stronger together
Hope, information and support for all affected by ALS
About ALS
Comprehensive information about the disease.
Our services
Learn how we can help and register to receive support.
For health care professionals
Information and resources to help you support your patients.
Newly diagnosed?
Bypass the internet searches and start here.
Resource centre
Cut through the online clutter! Our resource centre connects you with some of the best ALS resources the internet has to offer. Its easy-to-use filters help you quickly find websites, webinars, videos and other information tailored to the changing needs of people and families affected by ALS.

I want to help
There’s power in community, and so many ways to lend your support.
Walk to End ALS
Join our family-friendly and community-oriented events across the province
Ride to Fight ALS
Registration is now open for our flagship fundraiser
Create a fundraiser
Fundraise your own way or add a giving option to your activity
Volunteer
Time is your most precious gift. Use it to help the cause and community.

After her ALS diagnosis, and as her disease progressed, the ALS Society of Quebec was there for my mother and our family. One call with a professional counsellor and we got all the support, advice, and information about the disease we could possibly need. And it was very reassuring to know we weren’t alone. The many services they provide, and their role in advancing research into the disease, create something we all need to get through a time like this: hope.
Elias Makos,
Host of The Elias Makos Show on CJAD 800 and former caregiver to his mother, who passed away in 2021.
News and media

Health Canada Accepts for Review New Drug Submission…

Health Canada has agreed to review a New Drug Submission (NDS) for Tofersen, for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a mutation in the superoxide dismutase 1 (SOD1) gene. A regulatory decision on the New Drug Submission is expected in early 2025. If approved, this therapy will become the first treatment in Canada to target a genetic cause of ALS. Read the…
19 Mar 2024

A Message of Hope and Unity in the…

Today, Amylyx announced that their Phase 3 PHOENIX trial, a global, 48-week, randomized, placebo-controlled study of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine; also known as ALBRIOZA) in people living with ALS, did not meet its prespecified primary or secondary endpoints. It’s understandable if this outcome has left us all feeling disheartened and discouraged. Now, more than ever,…
8 Mar 2024